Plaintiff May Amend Warning, Fraud Claims in Truvada Action, Hawaii Federal Judge Rules



DOCUMENTS
  • Order


HONOLULU — A Hawaii federal judge has allowed the plaintiff in a case targeting Gilead Sciences Inc.’s HIV drug Truvada to replead his failure-to-warn claims, finding they are not preempted by federal law because the drug maker could have changed the label via the FDA’s Changes Being Effected process.

In an Aug. 31 order, Judge Derrick K. Watson of the U.S. District Court for the District of Hawaii further ruled that the plaintiff may amend his fraud and breach of warranty claims. However, the judge held that the design defect claims are preempted because Gilead could not unilaterally change the …

FIRM NAMES
  • Lyons Brandt Cook & Hiramatsu
  • Sidley Austin LLP





UPCOMING CONFERENCES




HarrisMartin's MDL Conference: The Current Mass Tort Landscape - Best Management Practices & Updates on Key Litigation

September 28, 2022 - St. Louis, MO
Four Seasons Hotel, St. Louis

MORE DETAILS



HarrisMartin's Webinar Series: The Hottest Upcoming Device Projects - Strattice Hernia Mesh & Exactech Hip Implants

November 09, 2022

MORE DETAILS